The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment completion and toxicity of trastuzumab or trastuzumab + lapatinib in older patients (pts): BIG 2-06; NCCTG N063D (Alliance).
 
Noam Falbel Ponde
No Relationships to Disclose
 
Dominique Agbor-Tarh
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Lissandra Dal Lago
Travel, Accommodations, Expenses - Roche
 
Larissa A. Korde
No Relationships to Disclose
 
Florentine Hilbers
Research Funding - Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)
 
Christian Jackisch
Consulting or Advisory Role - AstraZeneca; Genomic Health; Genomic Health; Novartis; Roche; Tesaro
Research Funding - Genomic Health (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis; Roche
 
Olena Werner
Employment - Novartis
 
Richard D. Gelber
Research Funding - AstraZeneca (Inst); Celgene (Inst); Ferring (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Aminah Jatoi
No Relationships to Disclose
 
Amylou C. Dueck
Consulting or Advisory Role - Bayer; Phytogine
Travel, Accommodations, Expenses - Pfizer
 
Alvaro Moreno-Aspitia
No Relationships to Disclose
 
Christos Sotiriou
Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; CEPHEID; Puma Biotechnology; Seagen; Vertex
Speakers' Bureau - Eisai; Foundation Medicine; Prime Oncology; Teva
Patents, Royalties, Other Intellectual Property - A companion diagnostic for CDK4/CDK6 inhibitory drugs based on CDK4 Phosphorylation. Which patient to be treated and how. PCT/EP2017/061780; Epigenetic portraits of human Breast Cancer, PCT/EP2012/050836, WO2012/098215
Travel, Accommodations, Expenses - Roche; Roche/Genentech; Roche/Genentech
 
Evandro de Azambuja
Honoraria - Roche/Genentech
Consulting or Advisory Role - Roche/Genentech
Research Funding - AstraZeneca (Inst); GlaxoSmithKline/Novartis (Inst); Roche/Genentech (Inst); Servier/Pfizer (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche/Genentech
 
Martine Piccart
Leadership - Radius Health
Honoraria - AstraZeneca; Camel-IDS; Crescendo Biologics; Debiopharm Group; G1 Therapeutics; HUYA Bioscience International; Immunomedics; Lilly; Menarini; MSD; Odonate Therapeutics; Oncolytics; Periphagen; Pfizer; PharmaMar; Roche; Seagen
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Roche (Inst); SERVIER (Inst); Synthon (Inst)